American Association for Cancer Research
00085472can192918-sup-229142_2_supp_6133670_q6mr8k.pdf (14.74 kB)

Supplementary Data from Hispanic/Latino Patients with Gastric Adenocarcinoma Have Distinct Molecular Profiles Including a High Rate of Germline CDH1 Variants

Download (14.74 kB)
journal contribution
posted on 2023-03-31, 03:22 authored by Sam C. Wang, Yunku Yeu, Suntrea T.G. Hammer, Shu Xiao, Min Zhu, Changjin Hong, Jean R. Clemenceau, Lynn Y. Yoon, Ibrahim Nassour, Jeanne Shen, Deepak Agarwal, Scott I. Reznik, John C. Mansour, Adam C. Yopp, Hao Zhu, Tae Hyun Hwang, Matthew R. Porembka

Supplementary Table Legend





University of Texas Lung Cancer

American Cancer Society

UT Southwestern



Hispanic/Latino patients have a higher incidence of gastric cancer and worse cancer-related outcomes compared with patients of other backgrounds. Whether there is a molecular basis for these disparities is unknown, as very few Hispanic/Latino patients have been included in previous studies. To determine the genomic landscape of gastric cancer in Hispanic/Latino patients, we performed whole-exome sequencing (WES) and RNA sequencing on tumor samples from 57 patients; germline analysis was conducted on 83 patients. The results were compared with data from Asian and White patients published by The Cancer Genome Atlas. Hispanic/Latino patients had a significantly larger proportion of genomically stable subtype tumors compared with Asian and White patients (65% vs. 21% vs. 20%, P < 0.001). Transcriptomic analysis identified molecular signatures that were prognostic. Of the 43 Hispanic/Latino patients with diffuse-type cancer, 7 (16%) had germline variants in CDH1. Variant carriers were significantly younger than noncarriers (41 vs. 50 years, P < 0.05). In silico algorithms predicted five variants to be deleterious. For two variants that were predicted to be benign, in vitro modeling demonstrated that these mutations conferred increased migratory capability, suggesting pathogenicity. Hispanic/Latino patients with gastric cancer possess unique genomic landscapes, including a high rate of CDH1 germline variants that may partially explain their aggressive clinical phenotypes. Individualized screening, genetic counseling, and treatment protocols based on patient ethnicity and race may be necessary. Gastric cancer in Hispanic/Latino patients has unique genomic profiles that may contribute to the aggressive clinical phenotypes seen in these patients.

Usage metrics

    Cancer Research



    Ref. manager